Physician profile
Sandhya Chanda
NPI 1043219710
$1,915.25
in general payments reported to CMS, 2019-2025
15 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $31.45 · 2021: $205 · 2022: $370 · 2023: $336 · 2024: $494 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,142.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,010.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $329.21 | 2021-2025 | |
| Abbott Laboratories | $125.53 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $83.45 | 2022-2023 | Xarelto |
| Astellas Pharma US INC | $75.54 | 2019-2024 | Veozah |
| Lilly USA, LLC | $71.97 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $39.20 | 2019-2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $35.70 | 2021-2022 | |
| Pfizer INC. | $28.51 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $27.44 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.46 | 2022 | |
| Glaxosmithkline, LLC. | $20.15 | 2023 | Arexvy, Trelegy Ellipta |
| Qorumpartners | $18.43 | 2022 | |
| Exact Sciences Corporation | $14.72 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Chanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.